The partnership, whose value was not disclosed, will leverage the real-world clinic-genomic database developed by Flatiron and Foundation Medicine, called CGDB, for both the potential identification of new therapeutic targets as well as help inform the design of future clinical trials.
Upon closing of the transaction, expected in the second quarter, CM Life Sciences will be renamed and its stock listed on Nasdaq global exchange. The deal values Sema4 at $2 billion.
When the pandemic heated up early last year, the UK Biobank set out to urgently gather data on COVID-19 diagnostic tests, deaths, and hospitals...
The researchers showed that men of African ancestry inherit about twice the prostate cancer risk on average compared to men of European ancestry. In contrast, men of Asian ancestry inherit about three-quarters the risk of their white counterparts.
The companies say that through AI-enhanced interrogation of medical literature and phenotypes associated with rare disease, researchers will be better able to make new and unexpected discoveries based on rare disease data.
The OneOncology Research Network (OneR), a subsidiary of OneOncology, will provide operational, regulatory, and research support services with the aim of more efficiently executing multi-center clinical trials.
Proceeds from the financing will allow SOPHiA to embark upon the next stage of its planned global expansion, aimed at satisfying growing clinical and biopharma demand for secure data pooling and knowledge sharing for healthcare professionals.
The GA4GH community has launched the Federated Analysis Systems Project, a collaborative effort between several work streams and driver projects to integrate multiple GA4GH standards and implement them at multiple institutions.
The new task order brings to about $175 million the cumulative value of task orders issued by the VA to Personalis, a Menlo Park, CA, company specializing in population sequencing and cancer genomics.
The study, published today in the American Journal of Human Genetics and details the extent to which the public are both unfamiliar with, and unwilling to participate in, genomic research.